Abstract Number: 1285 • ACR Convergence 2023
PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort
Background/Purpose: We have previously shown that PROMIS-29 physical (pain, fatigue) and emotional (depression, anxiety) symptom clusters can be used to identify 4 distinct early RA…Abstract Number: PP12 • ACR Convergence 2023
Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom
Background/Purpose: I was diagnosed with Sjögren's disease in 2015. I sought help from a rheumatologist after experiencing hand pain. I also had dry eyes and…Abstract Number: 1375 • ACR Convergence 2023
The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome
Background/Purpose: To investigate the prevalence of anti-thyroid autoantibodies, abnormal thyroid function, and their clinical impacts in Korean patients with primary Sjögren's syndrome (pSS). Methods: One…Abstract Number: PP16 • ACR Convergence 2023
Peer Health Coaches Help Scleroderma Patients Cope with Isolation
Background/Purpose: In 2011, I felt extremely isolated with my new diagnosis of diffuse systemic sclerosis and sought support online and in support groups. In addition…Abstract Number: 1381 • ACR Convergence 2023
Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome
Background/Purpose: Fatigue is one of the dominant symptoms of patients with Primary Sjogren's syndrome (pSS). However, whether fatigue is specific to pSS compared to secondary…Abstract Number: 1424 • ACR Convergence 2023
Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
Background/Purpose: Fatigue is commonly reported by PsA patients (pts) and contributes to disease burden. The fully human IL-23p19-subunit inhibitor guselkumab (GUS) induces clinically meaningful and…Abstract Number: 1575 • ACR Convergence 2023
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…Abstract Number: 1630 • ACR Convergence 2023
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…Abstract Number: 057 • 2023 Pediatric Rheumatology Symposium
A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…Abstract Number: 0390 • ACR Convergence 2022
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…Abstract Number: 2189 • ACR Convergence 2022
Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study
Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…Abstract Number: 0393 • ACR Convergence 2022
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
Background/Purpose: Treatment success from the patients' perspective has not been defined in psoriatic arthritis (PsA). The objective was to determine prevalence and associations of patient-reported…Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…Abstract Number: 0847 • ACR Convergence 2022
Association of Frontal Plane Trunk Motion During Gait with Abductor Strength, Fatigue, and Physical Activity in Women with Hip Osteoarthritis
Background/Purpose: We have previously reported that fatigue and hip abductor weakness are associated with reduced physical activity (PA) in women with hip osteoarthritis (OA). We…Abstract Number: 0971 • ACR Convergence 2022
Development of a Theory-based Educational Intervention for Fatigue in Systemic Lupus Erythematosus (SLE) Using Human-centered Design Methodology
Background/Purpose: Fatigue is a top concern of individuals with SLE and is a leading cause of work impairment and disability in this population. Although fatigue…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 16
- Next Page »
